Saratov JOURNAL of Medical and Scientific Research
Home

The combined application of biological therapy and methotrexate in case of escape phenomenon progressing

Year: 2015, volume 11 Issue: №3 Pages: 405-409
Heading: Dermatovenerology Article type: Short message
Authors: Ponich E.S., Kruglova L.S., Babushkin A.M.
Organization: BU Khanty-Mansi Autonomous District— Yugra «Khanty-Mansi clinical skin and venereologic dispensary»
Summary:

Aim: the study of the efficacy of methotrexate in patients with the "escape effect" during the ustekinumab therapy. Materials and Methods. The results of methotrexate at a dose of 15-20mg/week in treatment of 4 patients receiving biologic and developed "escape effect". Ustekinumab is used as a hypodermic injection at a dose of 45 mg for a body weight of a patient no more than 100 kg, and 90 mg of body weight over 100 kg, at the zero week, the 4th week and then every 12 weeks. Patients control meets the standard management of patients in biological therapy. Results. The study shows that in the case of the resistance progressing when applying preparations of biological therapy, methotrexate is useful at a dose of 15-20mg/week for up to 6 months. The combined use of biologic therapy and methotrexate in the treatment of patients with psoriasis vulgaris, "escape effect" contributes to the marked regression of clinical symptoms and allows to control the process long enough, which is confirmed by the dynamics of the index PASI, BRS and DLQI. The combined method is highly safe, as evidenced by the lack of inhibition of hematopoiesis, the normal level of hepatic transaminases and serum creatinine, which greatly improves patient compliance in this type of therapy. Conclusion. The article presents the data of the combined application of biological medication therapy (ustekinumab) and methotrexate for the treatment of patients with the common form of psoriasis vulgaris. In the case of the development of resistance of biological therapy recommended the appointment of methotrexate. The combined use of methotrexate and biologic therapy in the treatment of patients with psoriasis vulgaris contributes to marked regression of clinical symptoms and allows to control the process for a long time.

Keywords: biological therapy, BSA, methotrexate, PASI, psoriasis, quality of life, system therapy, ustekinumab

Bibliography:
1. Pujola RM, Puiq L, Daudin E. Mental health selfassess-ment in patients with moderate to severe psoriasis: an observational, multicenter study of 1164 patients in Spain (the VACAP Study). Actas Dermosifiliogr 2013 Dec; 104 (10): 897-903
2. Gottlieb A, Korman NJ, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2: Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologies. J Am Acad Dermatol 2008 (May); 58 (5): 851-864
3. Gottlieb A, MenterA, Mendelsohn A, etal. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet 2009; 373 (9664): 633-640
4. O'Neill JL, Kalb RE. Ustekinumab in the therapy of chronic plaque psoriasis. Biologies 2009; 3: 159-168
5. Puig L, Lopez A, Vilarrasa E, Garcia I. Efficacy of biologies in the treatment of moderate-to-severe plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials with different time points. JEADV2014; 28: 1633-1653
6. Mclnnes I, Kavanaugh A, Gottlieb A, et al. Ustekinumab in patients with active psoriatic arthritis: Results of the phase 3, multicenter, double-blind, placebo-controlled PSUMMIT I study. Ann Rheum Dis 2012; 71: 107-10
7. Laws PM, Warren RB. Ustekinumab for the treatment of psoriasis. Expert Rev Clin Immunol 2011 Mar; 7 (2): 155-64
8. Kurzeja M, Rudnicka L, Olszewska M. New interleukin-23 pathway inhibitors in dermatology: ustekinumab, briakinumab, and secukinumab. Am J Clin Dermatol 2011 Apr 1; 12 (2): 113-125
9. Yeilding N, Szapary P, Brodmerkel C, et al. Development of the IL-12/23 antagonist ustekinumab in psoriasis: past, present, and future perspectives. Ann N Y Acad Sci 2011 Mar; 1222 (1): 30-39
10. Kimball AB, Papp KA, Wasfi Y, et al. Long-term efficacy of ustekinumab in patients with moderate-tosevere psoriasis treated for up to 5 years in the PHOENIX 1 study. J Eur Acad Dermatol Venereol. 2013 Dec; 27 (12): 1535-45.

AttachmentSize
2015_03-01_405-409.pdf516.71 KB
All articles of the authors: Babushkin A.M. , Kruglova L.S. , Ponich E.S.

No votes yet